Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 250 versus UNIPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 250 versus UNIPEN.
AUGMENTIN '250' vs UNIPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to beta-lactamases, preventing hydrolysis of amoxicillin.
Unipen (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation and autolysin inhibition.
One 250 mg amoxicillin/125 mg clavulanate tablet orally every 8 hours for 7-10 days.
500 mg to 2 g orally or intravenously every 4 to 6 hours; maximum 12 g/day IV for serious infections.
None Documented
None Documented
Amoxicillin: 1.0-1.3 hours; clavulanate: 1.0-1.5 hours; prolonged in renal impairment (up to 7 hours for amoxicillin in anuria).
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria or severe renal impairment.
Renal: ~50-70% as amoxicillin, ~25-40% as clavulanate unchanged; biliary/fecal: minor (10-15% combined).
Renal: 70-90% unchanged via tubular secretion and glomerular filtration; biliary: minor (<10%); fecal: minimal.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic